TP53 and congestive heart failure: In conclusion, the study performed network pharmacology and molecular docking analysis to elucidate that in the anti-LC and CHF effects of PSD, the most important bioactive compound was quercetin, TP53 was the most important target, and the PI3K-AKT signaling pathway was the most critical pathway.